Atea Announces Update and Topline Results of MOONSONG Study Evaluating AT-527 for COVID-19 in the Outpatient Setting

TOKYO, October 20, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Atea issued a press release on October 19 regarding update and topline results of MOONSONG study evaluating the RNA polymerase inhibitor AT-527 for COVID-19 in the outpatient setting. Please refer to the link below for details of the press release: Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient Setting https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-update-and-topline-results-phase-2

The release as fetched from its publisher. chugai-pharm.co.jp ↗